IL9 and colonic neoplasm: To evaluate the antitumor efficacy of vvDD-IL-9, B6 mice were i.p. injected with MC38-luc colon cancer cells and these tumor-bearing mice were i.p. injected with vvDD or vvDD-IL-9 at a dose of 2.0 × 108 PFU/200 μL per mouse or 200 μL PBS (mock treatment) 5 days after tumor injection.